AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To $230 Million
Biotech firm AmacaThera has struck a worldwide deal with Pacira BioSciences to licence its long-acting non-opioid pain management platform, AMT-143, receiving a US$5 million upfront payment and up to US$225 million in future milestones. The agreement underscores AmacaThera's tunable hydrogel drug-delivery technology and sets the stage for Pacira to fund development, manufacturing and commercialisation of AMT-143, targeted for 2026.
Click here for DetailsPioneering next-generation tunable hydrogel solutions for precise, sustained drug delivery
AmacaThera’s clinically validated hydrogel drug delivery platform seamlessly integrates two well-established, biocompatible polymers, hyaluronic acid and methylcellulose, into a proprietary formulation. This innovative injectable hydrogel enables precise, localized, and sustained delivery of therapeutics, ensuring long-acting release exactly where it is needed. The platform is broadly compatible with a diverse array of therapeutic agents, including small molecules, biologics, enzymes, and cells. Its tunability allows for the fine adjustment of drug release parameters, such as rate, duration, and timing tailored to the unique requirements of each clinical application.
What We Do
Innovative Drug Delivery Platform
Next generation hydrogel-based drug delivery platform that enables precise, localized, and long-acting drug release for a wide range of therapeutics.
Broad Compatibility
Tunable platform works with small molecules, biologics, antibodies, peptides, nanoparticles, and cells, and is tailored for various clinical needs from post-surgical pain to oncology and beyond.
Clinically Validated Technology
Proven safety and efficacy through preclinical models and Phase 1 human trials, minimizing regulatory risk.
Scalable, Cost-Effective Manufacturing
Simple "mix and fill" process reduces production costs and easily scales to meet global demand.
Collaborative Partnership Model
Partner with pharma companies to advance products, generating value through upfront payments, milestones, and royalties while accelerating product development.
The Problem
+ AmacaThera’s solution
Problem:
Many therapies fall short because they cannot be delivered precisely, at the right dose, for long enough, or without unwanted side effects.
Solution:
AmacaThera’s hydrogel drug delivery platform forms an injectable depot at the target site, providing precise, localized, and sustained delivery of therapeutics and minimising exposure elsewhere in the body.
Platform | Technology Highlights
Injectable Depot
Our shear-thinning hydrogel can be delivered via standard syringe and sets into a depot at body temperature.
Broad Payload Compatibility
From small molecules to biologics, stem cells to enzymes — our platform accommodates varied therapeutic modalities.
Advanced Drug Delivery
Designed to access anatomical areas like incision sites, brain/ eye tissue and other underserved locations.
Strong IP & GMP Readiness
A robust IP portfolio and manufactured at GMP-scale sets us apart.
Frequently asked questions
To revolutionize drug delivery with our injectable hydrogel technology — extending the life and performance of therapeutics across multiple indications.
Partners
Partnerships foster collaboration at the highest level.
AmacaThera seeks to partner with like minded companies to co-develop new, exciting products that provide on-time, on-target therapeutic solutions.
Get in touchNews
AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery Platform
AmacaThera receives US$5 million upfront and up to US$225 million in potential future milestone payments with Pacira BioSciences for AMT-143, AmacaThera's long-acting non-opioid anesthetic for post-operative pain.